Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients.
Michele Orditura(University of Campania "Luigi Vanvitelli"), Giuseppe Catalano, Berardo Sarubbi(Parthenope University of Naples), Valentino Ducceschi(Società Italiana di Cardiologia), A Iacono, Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), A. Auriemma(University of Verona), Stefania Infusino(Ospedale SS. Annunziata)
Cited by 9
Related Papers
Treatment of gastric cancer
|World Journal of Gastroenterology|2014|628
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|347
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|285
Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension
|International Journal of Cardiology|2013|242